Sign in or Register
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our Core Values
    • Our milestones
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Clinical Candidates from Partnered Programs
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
Aurigene
Home
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our Core Values
    • Our milestones
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Clinical Candidates from Partnered Programs
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us

SMARCA

Our Publications

Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia

AACR; 2022

Read More

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

AACR; 2022

Read More

Targeting SWI/SNF ATPases in enhancer-addicted human cancers

AACR; 2022

Read More

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Nature; 2022; 434–439

Read More

Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency

AACR; 2021

Read More

In silico designing of targeted protein degraders

Modern Approaches in Drug Designing; 2021

Read More

In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4

EORTC-NCI AACR; 2018

Read More

Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)

AACR; 2018

Read More
Home
  • Pipeline
  • Publications
  • Science
  • News and Events
  • Careers
Careers
Contact Us
Linkedin X-twitter

Governance

Code of Business Conduct
and Ethics

  • Statement of Policy
  • Link to Raise Concerns

Annual Reports

  • Link to View Report

Safety, Health, Environment
and Sustainability

  • Policy Statement and Reports

Information Security
Management System

  • ISO/IEC 27001:2022 Certificate

Policies

CSR

  • Commitee
  • Statement of Policy
  • Guiding Principles
  • Activities

Remuneration Policy

  • Statement of Policy

© 2022 Aurigene Discovery Technologies

Privacy & GDPR policy

Cookie policy

Crafted by: Pink Lemonade Communications Pvt. Ltd.

© 2022 Aurigene Oncology

Privacy and GDPR Policy

Cookie Policy

Apply Now